The COURAGE trial showed no substantial difference in cardiovascular outcomes among patients who received either optimal medical therapy or optimal therapy plus a percutaneous intervention. Dr. William Weintraub, professor of medicine at Chrisitana Care Health System in Newark, Delaware, describes his cost-benefit analysis of this trial and how cost effectiveness should be measured and evaluated in this patient population. Hosted by Dr. Matthew Sorrentino.
A Cost-Benefit Analysis of Angioplasty
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Details
Presenters
Overview
The COURAGE trial showed no substantial difference in cardiovascular outcomes among patients who received either optimal medical therapy or optimal therapy plus a percutaneous intervention. Dr. William Weintraub, professor of medicine at Chrisitana Care Health System in Newark, Delaware, describes his cost-benefit analysis of this trial and how cost effectiveness should be measured and evaluated in this patient population. Hosted by Dr. Matthew Sorrentino.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?